DK0865294T3 - Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater - Google Patents

Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater

Info

Publication number: DK0865294T3
Authority: DK; Denmark
Prior art keywords: methods; reducing; reduced levels; protein preparations; blood lipids
Prior art date: 1995-08-17

Application number

DK96926873T

Other languages

English (en)

Inventor

Mary Ann Pelleymounter

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-17

Filing date

1996-08-02

Publication date

2004-06-28

1996-08-02 Application filed by Amgen Inc filed Critical Amgen Inc

2004-06-28 Application granted granted Critical

2004-06-28 Publication of DK0865294T3 publication Critical patent/DK0865294T3/da

Links

238000000034 method Methods 0.000 title abstract 3
102000016267 Leptin Human genes 0.000 title abstract 2
108010092277 Leptin Proteins 0.000 title abstract 2
239000008280 blood Substances 0.000 title abstract 2
210000004369 blood Anatomy 0.000 title abstract 2
150000002632 lipids Chemical class 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
206010020772 Hypertension Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
208000001130 gallstones Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003626 triacylglycerols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

DK96926873T 1995-08-17 1996-08-02 Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater DK0865294T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51626395A	1995-08-17	1995-08-17
PCT/US1996/012674 WO1997006816A1 (en)	1995-08-17	1996-08-02	Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions

Publications (1)

Publication Number	Publication Date
DK0865294T3 true DK0865294T3 (da)	2004-06-28

Family

ID=24054813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96926873T DK0865294T3 (da)	1995-08-17	1996-08-02	Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater

Country Status (13)

Country	Link
US (1)	US20020147142A1 (da)
EP (1)	EP0865294B1 (da)
JP (1)	JP4173913B2 (da)
AT (1)	ATE259650T1 (da)
AU (1)	AU6688896A (da)
CA (1)	CA2229450A1 (da)
DE (1)	DE69631605T2 (da)
DK (1)	DK0865294T3 (da)
ES (1)	ES2216055T3 (da)
MX (1)	MX9801159A (da)
PT (1)	PT865294E (da)
WO (1)	WO1997006816A1 (da)
ZA (1)	ZA966798B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429290B1 (en)	1994-08-17	2002-08-06	The Rockefeller University	OB polypeptides, modified forms and derivatives
US6001968A (en)	1994-08-17	1999-12-14	The Rockefeller University	OB polypeptides, modified forms and compositions
AU6284896A (en) *	1995-06-22	1997-01-22	Eli Lilly And Company	Obesity protein intermediates and their preparation and use
US5830450A (en) *	1996-06-19	1998-11-03	Lallone; Roger L.	Compositions of leptin bound to an apolipoprotein
US7332338B2 (en)	1996-10-04	2008-02-19	Lexicon Pharmaceuticals, Inc.	Vectors for making genomic modifications
US20020019352A1 (en) *	1997-04-17	2002-02-14	David N. Brems	Stable, active, human ob protein compositions and methods
US6017876A (en)	1997-08-15	2000-01-25	Amgen Inc.	Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6808921B1 (en)	1998-03-27	2004-10-26	Lexicon Genetics Incorporated	Vectors for gene mutagenesis and gene discovery
US6436707B1 (en)	1998-03-27	2002-08-20	Lexicon Genetics Incorporated	Vectors for gene mutagenesis and gene discovery
US6541033B1 (en)	1998-06-30	2003-04-01	Amgen Inc.	Thermosensitive biodegradable hydrogels for sustained delivery of leptin
CA2337667C (en) *	1998-08-10	2008-04-29	Amgen Inc.	Dextran-leptin conjugates, pharmaceutical compositions and related methods
US6210924B1 (en)	1998-08-11	2001-04-03	Amgen Inc.	Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en)	1998-10-14	2002-07-16	Amgen Inc.	Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en)	1998-12-23	2001-06-12	Amgen Inc.	Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU782230B2 (en)	1999-09-22	2005-07-14	Serono Genetics Institute S.A.	Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
ATE475094T1 (de)	2001-10-22	2010-08-15	Amgen Inc	Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
ATE486842T1 (de)	2002-03-12	2010-11-15	Merck Sharp & Dohme	Substituierte amide
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1462116A1 (en) *	2003-03-29	2004-09-29	Villitech SARL	Composition for treating the gastrointestinal tract
GB0307367D0 (en) *	2003-03-29	2003-05-07	Twg	Composition and method for treating the gastro-intestinal tract
CA2552241C (en)	2003-12-30	2013-10-01	Durect Corporation	Co-polymeric devices for controlled release of active agents
DK1814590T4 (da)	2004-11-01	2014-02-24	Amylin Pharmaceuticals Llc	Behandling af obesitet og beslægtede sygdomme.
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US7629315B2 (en) *	2005-03-09	2009-12-08	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2009149379A2 (en)	2008-06-05	2009-12-10	Regents Of The University Of Michigan	Use of leptin for the treatment of fatty liver diseases and conditions
MX349054B (es)	2010-09-28	2017-07-07	Aegerion Pharmaceuticals Inc	Leptinas altamente solubles.
CN111529535A (zh)	2012-09-27	2020-08-14	儿童医学中心公司	用于治疗肥胖症的化合物和其使用方法
PT3074033T (pt)	2013-11-26	2019-02-08	Childrens Medical Ct Corp	Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en)	2014-04-03	2017-07-27	The Children's Medical Center Corporation	Hsp90 inhibitors for the treatment of obesity and methods of use thereof
DK3509624T3 (da)	2016-09-12	2023-11-13	Amryt Pharmaceuticals Inc	Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6309853B1 (en) *	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

1996
- 1996-08-02 WO PCT/US1996/012674 patent/WO1997006816A1/en not_active Ceased
- 1996-08-02 JP JP50931997A patent/JP4173913B2/ja not_active Expired - Fee Related
- 1996-08-02 CA CA002229450A patent/CA2229450A1/en not_active Abandoned
- 1996-08-02 ES ES96926873T patent/ES2216055T3/es not_active Expired - Lifetime
- 1996-08-02 PT PT96926873T patent/PT865294E/pt unknown
- 1996-08-02 AU AU66888/96A patent/AU6688896A/en not_active Abandoned
- 1996-08-02 AT AT96926873T patent/ATE259650T1/de not_active IP Right Cessation
- 1996-08-02 DK DK96926873T patent/DK0865294T3/da active
- 1996-08-02 EP EP96926873A patent/EP0865294B1/en not_active Expired - Lifetime
- 1996-08-02 DE DE69631605T patent/DE69631605T2/de not_active Expired - Fee Related
- 1996-08-02 MX MX9801159A patent/MX9801159A/es not_active IP Right Cessation
- 1996-08-12 ZA ZA9606798A patent/ZA966798B/xx unknown
2001
- 2001-05-07 US US09/850,433 patent/US20020147142A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX9801159A (es)	1998-05-31
US20020147142A1 (en)	2002-10-10
PT865294E (pt)	2004-07-30
JPH11511165A (ja)	1999-09-28
CA2229450A1 (en)	1997-02-27
JP4173913B2 (ja)	2008-10-29
ATE259650T1 (de)	2004-03-15
ZA966798B (en)	1997-02-19
ES2216055T3 (es)	2004-10-16
DE69631605T2 (de)	2005-01-05
AU6688896A (en)	1997-03-12
DE69631605D1 (de)	2004-03-25
WO1997006816A1 (en)	1997-02-27
EP0865294B1 (en)	2004-02-18
EP0865294A1 (en)	1998-09-23

Publication	Publication Date	Title
ZA966798B (en)	1997-02-19	Methods of reducing or maintaining reduced levels of blood lipids using OB protein compositions.
DK0833649T3 (da)	2003-04-07	Proteinhydrolysatpræparater til forebyggelse eller behandling af allergier og fremgangsmåder til fremstilling og anvendelser deraf
NO951761L (no)	1995-11-07	Stabilt preparat for behandling av blodkoagulasjonssykdommer
ATE198050T1 (de)	2000-12-15	Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE202706T1 (de)	2001-07-15	Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69625691D1 (de)	2003-02-13	Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
BR9907995A (pt)	2001-05-15	Métodos imunológicos para modular miostatina em sujeitos vertebrados
DE69827192D1 (de)	2004-12-02	Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DK1368060T3 (da)	2010-08-30	HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
AU1049788A (en)	1988-06-30	Methods and peptides for the treatment of non-ige-mediated diseases
NO983999D0 (no)	1998-08-31	Peptidimmunogener for vaksinasjon mot og behandling av allergi
ATE116848T1 (de)	1995-01-15	Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
NO970532D0 (no)	1997-02-06	System og metode for blodbehandling
DE69434777D1 (de)	2006-08-10	Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
ATE139226T1 (de)	1996-06-15	Aminosulfonylharnstoff-acat-inhibitoren
HUP9900506A2 (hu)	1999-06-28	Protrombinszármazékok
DK0740547T3 (da)	1999-09-27	Liposomer indeholdende deri indkapslede proteiner, fremgangsmåde til deres fremstilling, samt farmaceutiske og kosmetiske p
EP0680763A3 (en)	1998-01-28	Stable preparation for the treatment of blood coagulation disorders comprising an activated coagulation factor and lipid vesicles
DE69721484D1 (de)	2003-06-05	Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
ATE293994T1 (de)	2005-05-15	Multivalente rekombinante antikörper zur behandlung von hrv infektionen
NO992531L (no)	1999-07-27	Fremgangsmåter ved fremstilling av rekombinant protein
DE69734349D1 (de)	2006-02-23	Behandlung von knochenleiden mit adrenomedullin
NO874320D0 (no)	1987-10-16	Fremgangsmaate for bestemmelse av funksjonelle nivaaer av protein c i humant plasma.
UA31401A (uk)	2000-12-15	Спосіб хірургічного лікування портальної гіпертензії
DE69601456D1 (de)	1999-03-11	Verfahren zur Herstellung von optisch aktiven 3-Hydroxy-1,5-Benzothiazepinderivaten sowie Zwischenprodukte in diesem Verfahren